公司新闻

最新信息

未分类

北极星药业 申请第一上市

Polaris Group北极星药业-KY(6550)赶在2021年结束前向台湾证交所送件申请股票第一上市

了解更多
未分类

北极星肺癌临床第三阶段期中分析达最高标,获得药证指日可待

北极星-KY(6550)在美国进行的肺间皮癌(肺癌的一种)临床试验三期期中分析报告于美国时间2月25日出炉,以现有期中的数据来分析,预估最后整体试验的成功机率在80%以上(80~100%之间)。

了解更多
未分类

Polaris Group Has Entered Into An Agreement With The University Of California,Irvine(UCI) To Develop A Universal Influenza And Coronavirus Vaccine.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

了解更多
未分类

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas

SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI‑PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas. The results were presented by Dr. Peter Szlosarek from Barts Cancer Center in the UK (abstract No.2589) at the American Society Clinical Oncology’s 2018 annual meeting.

了解更多
Scroll to Top